Pfizer shuts India cancer drug plant for up to two years, worsening drug shortages

Pfizer has temporarily closed a manufacturing site in India that produces several cancer medicines.

The company says the facility will remain idle for as long as two years while it addresses the issues that forced the shutdown.

The pause adds to existing shortages of oncology drugs, raising concerns among patients and healthcare providers about treatment continuity.

The closure follows heavy monsoon rains that damaged the plant, prompting the precautionary halt.

Analysts warn the prolonged outage could affect Pfizer's position in the oncology market and may draw regulatory attention to supply‑chain vulnerabilities.